RECRUITINGOBSERVATIONAL
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
About This Trial
The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.
Who May Be Eligible (Plain English)
Who May Qualify:
- Adult participants 19 years of age or older
- Participants who receive mavacamten according to the approved product label
- Participants who sign the willing to sign a consent form form
Who Should NOT Join This Trial:
- Participants who are prescribed mavacamten for therapeutic indications not approved in Korea
- Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Adult participants 19 years of age or older
* Participants who receive mavacamten according to the approved product label
* Participants who sign the informed consent form
Exclusion Criteria:
* Participants who are prescribed mavacamten for therapeutic indications not approved in Korea
* Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety
Treatments Being Tested
DRUG
Mavacamten
According to approved product label
Locations (2)
Local Institution - 0001
Seoul, South Korea
Novotech Laboratory Korea Co., Ltd.
Seoul, South Korea